Education
About Us
Working with TipRanks
Follow Us
Vivos Therapeutics (VVOS)
NASDAQ:VVOS
VVOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.98 - $7.95
Previous CloseN/A
Volume144.69K
Average Volume (3M)198.65K
Market Cap
$35.20M
Enterprise Value$35.89M
Total Cash (Recent Filing)$2.34M
Total Debt (Recent Filing)$1.40M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Nov 12, 2025EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding7,504,807
10 Day Avg. Volume189,048
30 Day Avg. Volume198,654
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue2.45
Enterprise Value/Gross Profit4.18
Enterprise Value/Ebitda-3.41
Forecast
1Y Price Target
$4.50Price Target Upside-3.02% Downside
Rating ConsensusHold
Number of Analyst Covering0
Bulls Say, Bears Say
Bulls Say
Cost ControlOperating expenses in Q4 FY24 were down 21% yoy to $4.9 million, reflecting the company’s ongoing focus on cost control.
Regulatory ApprovalsFDA approves use of Vivos CARE appliances to treat moderate to severe OSA in children, a first in the industry.
Revenue GrowthVivos's new selling model can result in 4-6 times as much revenue per case while accessing many more patients with healthy margins.
Bears Say
Financing ConcernsThe need for additional financing presents the likelihood of further dilutive financing in the next few quarters.
Operational StrategyThe company is transitioning its go-to-market strategy to direct alliances with sleep medicine specialists, aiming to expand its sleep testing partnership nationally.
Vivos Therapeutics News
VVOS FAQ
What was Vivos Therapeutics’s price range in the past 12 months?
Vivos Therapeutics lowest stock price was $1.98 and its highest was $7.95 in the past 12 months.
What is Vivos Therapeutics’s market cap?
Vivos Therapeutics’s market cap is $35.20M.
When is Vivos Therapeutics’s upcoming earnings report date?
Vivos Therapeutics’s upcoming earnings report date is Nov 12, 2025 which is in 74 days.
How were Vivos Therapeutics’s earnings last quarter?
Vivos Therapeutics released its earnings results on Aug 19, 2025. The company reported -$0.55 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$0.17.
Is Vivos Therapeutics overvalued?
According to Wall Street analysts Vivos Therapeutics’s price is currently Overvalued.
Does Vivos Therapeutics pay dividends?
Vivos Therapeutics does not currently pay dividends.
What is Vivos Therapeutics’s EPS estimate?
Vivos Therapeutics’s EPS estimate is -0.48.
How many shares outstanding does Vivos Therapeutics have?
Vivos Therapeutics has 7,504,807 shares outstanding.
What happened to Vivos Therapeutics’s price movement after its last earnings report?
Vivos Therapeutics reported an EPS of -$0.55 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went down -3.279%.
Which hedge fund is a major shareholder of Vivos Therapeutics?
Currently, no hedge funds are holding shares in VVOS
Vivos Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.50 (-3.02% Downside)
$4.50 (-3.02% Downside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.46%
12-Months-Change
Fundamentals
Return on Equity
-262.03%
Trailing 12-Months
Asset Growth
64.33%
Trailing 12-Months
Company Description
Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology company specializing in the development and commercialization of treatments for obstructive sleep apnea (OSA) and related sleep disorders. The company leverages its proprietary Vivos System, which combines cutting-edge oral appliance technology with a multidisciplinary therapeutic protocol to address the underlying causes of OSA. Vivos operates within the healthcare sector, focusing primarily on dental and medical practices to deliver its innovative solutions.
VVOS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a period of transition for Vivos Therapeutics, with significant investments and strategic changes aimed at long-term growth through the SCN acquisition and deployment of SO teams. While the company has secured financing and reports early success with SCN, current financial performance has been negatively impacted by decreased revenue and increased operating losses.View all VVOS earnings summariesTechnical Analysis
Accelerate Diagnostics
―
Co-Diagnostics
―
PAVmed
―
BioSig Technologies
―
Adagio Medical Holdings
―
Ownership Overview
1.24%
Insiders
1.39% Mutual Funds
<0.01% Other Institutional Investors
96.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---